<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305522</url>
  </required_header>
  <id_info>
    <org_study_id>MIGR_PRO.2</org_study_id>
    <nct_id>NCT04305522</nct_id>
  </id_info>
  <brief_title>Probiotics for the Prophylaxis of Migraine</brief_title>
  <acronym>MIGR_PRO2</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Two Probiotic Interventions For The Prophylaxis of Migraine in Patients Diagnosed With Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biopolis S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biopolis S.L.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to understand the efficacy of two probiotic interventions as prophylaxes of
      migraine symptoms in individuals diagnosed with episodic migraine.

      The primary outcome measure will be migraine days per month, but secondary outcome measures
      such as use of analgesia, the wider impact of migraine (as assessed through the HIT-6 score)
      will also be assessed. Finally adverse effects will be evaluated.

      The study will have three arms: two arms including the two different probiotic preparations
      and a third placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2, 2020</start_date>
  <completion_date type="Anticipated">May 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days with migraine episodes</measure>
    <time_frame>4-week</time_frame>
    <description>Number of days with migraine episodes in weeks 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of days with migraine episodes</measure>
    <time_frame>8-week</time_frame>
    <description>Number of days with migraine episodes, in weeks 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of days with migraine episodes</measure>
    <time_frame>12-week</time_frame>
    <description>Number of days with migraine episodes, in weeks 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of migraine episodes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of migraine episodes, in weeks 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of migraine episodes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of migraine episodes, in weeks 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of migraine episodes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of migraine episodes, in weeks 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days that each patient requires the administration analgesia</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of days that each patient requires the administration analgesia, in weeks 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days that each patient requires the administration analgesia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of days that each patient requires the administration analgesia, in weeks 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days that each patient requires the administration analgesia</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of days that each patient requires the administration analgesia, in weeks 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Impact Test (HIT-6) score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Headache Impact Test (HIT-6) score at weeks 0 and 4 Little or no impact (46 or less) Some impact (50 -55) Substantial impact (56-59) Severe impact (60-78)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Impact Test (HIT-6) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Headache Impact Test (HIT-6) score at weeks 8 Little or no impact (46 or less) Some impact (50 -55) Substantial impact (56-59) Severe impact (60-78)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Impact Test (HIT-6) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Headache Impact Test (HIT-6) score at weeks 12 Little or no impact (46 or less) Some impact (50 -55) Substantial impact (56-59) Severe impact (60-78)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment adherence rate using the returned capsules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Numbre od adverse effects reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of treatment intake days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Probiotic 1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A commercially-available multi-strain probiotic with added magnesium and vitamin B6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 2 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A multi-strain probiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic 1</intervention_name>
    <description>Probiotic mixture with maltodextrin as a carrier.</description>
    <arm_group_label>Probiotic 1 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator with maltodextrin as a carrier.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic 2</intervention_name>
    <description>Probiotic mixture with maltodextrin as a carrier.</description>
    <arm_group_label>Probiotic 2 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 - 65 years.

          2. Signature of informed consent by the patient.

          3. Patients with confirmed migraine, diagnosed by a neurologist

          4. Patient-indicated frequency of migraine attacks (or days) of at least 4 per month.

          5. Fairly predictable and stable pattern of migraine attacks (frequency, duration,
             intensity)

        Exclusion Criteria:

          1. Patients diagnosed with chronic migraine

          2. Migraine patients suffering from medication-dependent headaches.

          3. Patients suffering from cluster or tension-related headaches.

          4. Patients who used antibiotics up to two weeks before the start of the study.

          5. Patients who have taken other probiotics in the previous two months.

          6. Patients with chronic use of non-steroidal anti-inflammatory drugs.

          7. Patients with inflammatory bowel disease (due to increased intestinal permeability).

          8. Patients who are pregnant, breastfeeding or who do not commit to using an effective
             method of contraception during the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>María Empar Chenoll, PhD</last_name>
    <phone>+34 673 53 53 44</phone>
    <email>maria.chenoll@adm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario del Vinalopó</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03293</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana López García</last_name>
    </contact>
    <investigator>
      <last_name>Ana López García, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Erika Maria Torres San Narciso</last_name>
    </contact>
    <investigator>
      <last_name>Erika Maria Torres San Narciso, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

